COVID19: Abiraterone acetate (Zytiga)
Abiraterone acetate (Zytiga) can be used to treat some people who have prostrate cancer.
Page updated: 30 March 2020
Renewal of Special Authority
We have amended the renewal criteria for abiterone acetate (Zytiga) so that PSA testing is not necessary for ongoing funding. This change comes into effect on 1 April 2020.
Change to Section B of the Pharmaceutical Schedule
(strikethrough shows deletion from current criteria)
Renewal — (abiraterone acetate) only from a medical oncologist, radiation oncologist, urologist or medical practitioner on the recommendation of a medical oncologist, radiation oncologist or urologist. Approvals valid for 6 months for applications meeting the following criteria:
All of the following:
Significant decrease in serum PSA from baseline; and
- No evidence of clinical disease progression; and
- No initiation of taxane chemotherapy with abiraterone; and
- The treatment remains appropriate and the patient is benefiting from treatment.
Section H of the Pharmaceutical Schedule will also be amended to reflect this change.
Changes are temporary
We intend change the criteria back to the current status once health services have stabilised to a point where it becomes practical to reinstate them.
Who to contact
If you have any questions about this change, email firstname.lastname@example.org
Last updated: 15 April 2020